Sustainability Report

The report highlights Tigermed's 2019 scale and growth, reporting operating revenue of 28.03 RMB 100 million and 4,959 active employees. It describes the company's clinical-research contribution, including participation in 319 Class I Chinese innovative-drug projects and support for 36 drugs approved for market. The report also describes board diversity, with three female directors among six directors after the April 2020 re-election. Environmental indicators are disclosed for three offices, with the report noting that statistics will gradually expand to cover the entire group.